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When airborne bacteria are inhaled into the lungs they are 
quickly taken up by resident dendritic cells (DCs), which 
ferry bacterial antigens to the lymph nodes. Once in the 
lymph node, DCs produce interleukin (IL)-12p70 to help 
activate bug-specific T helper (Th)-1 cells. 
According to Khader and colleagues on page 
1805, DCs also use homodimers of the p40 
subunit of IL-12p70 to help them embark 
on their journey from lung to lymph node.
The production of bioactive IL-12p70—
which is composed of p40 and p35 subunits—
is required for protection against Mycobacterium 
tuberculosis (Mtb) infection in both mice and 
men. Without IL-12p35 and p40, protective 
Th1 cells are not activated and bacterial growth 
goes unchecked.
Mice expressing only p40, however, fare 
better than those lacking both subunits, de-
spite their inability to produce bioactive IL-12p70. This 
survival advantage is in part because p40 is one half of yet 
another Th-1–promoting cytokine (IL-23). Now, Khader 
et al. show that p40 homodimers also trigger the migration 
of Mtb-exposed DCs from the lung to the 
lymph nodes. This finding may help explain 
the observation that p40 alone is produced 
early and in high amounts in several models 
of lung inflammation, even though it blocks 
IL-12p70 signaling.
Only DCs that express p40 were able to 
respond to the chemokines CCL19 and 
CCL21, which normally coax DCs into the 
lymph nodes. DCs lacking p40 produced ex-
cess IL-10, which might explain their ambiva-
lence to chemokines as IL-10 was recently 
shown to short-circuit chemokine receptor 
signaling in human DCs and monocytes. 
Lung DCs that lack IL-12p40 
fail to migrate to lymph nodes in 
response to challenge with Mtb.
Dendritic cell paralysis
Melanomas disable DCs
T cells need to be activated by dendritic cells (DCs) 
before they will attack a tumor. Sumimoto et al. (page 
1651) now show that a common skin cancer mutation 
interferes with this pathway, thus helping the tumor to 
evade the body’s immune defenses.
Activating point mutations in the serine-threonine 
kinase BRAF are found in 66% of all malignant melano-
mas. The resulting activation of BRAF-ERK-MAPK 
signaling—the primary pathway involved in growth 
factor–induced proliferation of melanocytes—immor-
talizes the cells.
One BRAF mutation (BRAFV600E), according to Sum-
imoto and colleagues, also prompts human tumor cells to 
produce vascular endothelial growth factor, interleukin 
(IL)-6 and IL-10, all of which inhibit the production of 
proinflammatory cytokines by dendritic cells (DCs).
Disabling DCs, and thereby preventing their activa-
tion of tumor-specific T cells, is a popular tumor cell trick. 
Indeed, activation of the transcription factor STAT3—
common among hematopoietic and epithelial cancers—
triggers the production of a similar array of DC-inhibiting 
cytokines. In that model, blocking STAT3 in tumor-
bearing mice resulted in T cell attack on the tumor. 
Whether blocking BRAF will have the same reinvigorat-
ing effect on melanoma-specific T cells awaits the devel-
opment of an animal model.
Interfering with BRAF signaling might enhance im-
mune-activating antitumor therapies, such as DC im-
munization or T cell immunotherapy, as activation of 
the cells induced by these approaches might otherwise 
be blunted by the tumor’s suppressive output. 
T cells get energized
Many cell types use AMPK (AMP-activated protein kinase) to signal 
that energy reserves are low so more energy generation is needed. 
But, say Tamás et al. on page 1665, T cells also use AMPK to signal 
that energy will be needed in the near future, for attacking target 
cells, proliferating or churning out cytokines.
When cellular energy is in short supply—due, for example, to 
nutrient deficiency or metabolic stress—rising levels of AMP and 
falling levels of ATP trigger the activation of AMPK. AMPK then 
activates ATP-generating pathways, such as fatty acid oxidation. 
Tamás and colleagues now show that this pathway is also 
activated in T cells when their energy reserves dwindle. This is the 
first demonstration of physiological AMPK regulation in T cells.
But T cells turned on AMPK not only in response to falling 
energy levels but also in anticipation of upcoming energy needs. 
“If a T cell fluxes calcium,” says senior author Doreen Cantrell, “it is 
indicating that it is about to activate and will need ATP.” And this 
Ca2+ flux, they found, triggered the activation of AMPK.
Ca2+-induced AMPK activation required upstream Ca2+/
calmodulin-dependent protein kinase kinases, which were not needed 
for AMPK activation in response to rising AMP/ATP ratios. PI3 kinase 
(PI3K)—an enzyme required for cytokine- and costimulation-induced 
energy generation in T 
cells—was also dispensable 
for AMPK activation. 
Determining the 
importance of the AMPK 
pathway, relative to these 
other energy-boosting 
pathways, awaits the 
development of con  ditional 
AMPK-deficient mice. 
AMPK gets phosphorylated (and thus 
activated) after TCR ligation (α-CD3) 
in primary T cells.